Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Nutritional recommendations for gout: An update from clinical epidemiology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Lupus nephritis and pregnancy outcome

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Rosanne A van Schaarenburg
  • Lone Schejbel
  • Lennart Truedsson
  • Rezan Topaloglu
  • Sulaiman M Al-Mayouf
  • Andrew Riordan
  • Anna Simon
  • Maryam Kallel-Sellami
  • Peter D Arkwright
  • Anders Åhlin
  • Stefan Hagelberg
  • Susan Nielsen
  • Alexander Shayesteh
  • Adelaida Morales
  • Schuman Tam
  • Ferah Genel
  • Stefan Berg
  • Arnoldus G Ketel
  • J Merlijn van den Berg
  • Taco W Kuijpers
  • Richard F Olsson
  • Tom W J Huizinga
  • Arjan C Lankester
  • Leendert A Trouw
Vis graf over relationer

OBJECTIVE: Globally approximately 60 cases of C1q deficiency have been described with a high prevalence of Systemic Lupus Erythematosus (SLE). So far treatment has been guided by the clinical presentation rather than the underlying C1q deficiency. Recently, it was shown that C1q production can be restored by allogeneic hematopoietic stem cell transplantation. Current literature lacks information on disease progression and quality of life of C1q deficient persons which is of major importance to guide clinicians taking care of patients with this rare disease.

METHODS: We performed an international survey, of clinicians treating C1q deficient patients. A high response rate of >70% of the contacted clinicians yielded information on 45 patients with C1q deficiency of which 25 are published.

RESULTS: Follow-up data of 45 patients from 31 families was obtained for a median of 11 years after diagnosis. Of these patients 36 (80%) suffer from SLE, of which 16 suffer from SLE and infections, 5 (11%) suffer from infections only and 4 (9%) have no symptoms. In total 9 (20%) of the C1q deficient individuals had died. All except for one died before the age of 20 years. Estimated survival times suggest 20% case-fatality before the age of 20, and at least 50% of patients are expected to reach their middle ages.

CONCLUSION: Here we report the largest phenotypic data set on C1q deficiency to date, revealing high variance; with high mortality but also a subset of patients with an excellent prognosis. Management of C1q deficiency requires a personalized approach.

OriginalsprogEngelsk
TidsskriftJournal of Autoimmunity
Vol/bind62
Sider (fra-til)39-44
Antal sider6
ISSN0896-8411
DOI
StatusUdgivet - aug. 2015

ID: 46272288